The National Healthcare Security Administration (NHSA) has announced the completion of the expert review stage for drugs under consideration for inclusion in the upcoming update to the National Reimbursement Drug List (NRDL). This marks a significant step forward in the annual process, which determines which medications will be covered by national insurance.
Categorization and Submission Guidelines
The drugs that remain in contention have been categorized into four distinct groups: “simple renewals,” “renegotiation of existing listings,” “new listings requiring negotiation,” and “new listings via price bidding.” Manufacturers are advised to access the Application Module to download the “Confirmation Letter Template” and “Qualification Materials.” These documents must be completed and submitted electronically by the end of October 15, 2023. Original copies of the submitted materials should be mailed to the NHSA.
Deadlines and Negotiation Process
For those manufacturers who have confirmed their participation in the negotiation and price bidding process, it is crucial to submit all required materials to the NHSA before the end of October 22, 2023. Adherence to these deadlines is essential to ensure that the drugs are considered for inclusion in the NRDL.
Conclusion
The NHSA’s announcement underscores the importance of a timely and orderly submission process for drug manufacturers. As the deadline approaches, manufacturers must ensure compliance with all requirements to secure reimbursement status for their products in the National Reimbursement Drug List, thereby impacting patient access to essential medications.-Fineline Info & Tech
